ABSTRACT
Elevated IOP is the most important risk factor for irreversible blindness in patients with glaucoma; therefore, the aggressive treatment of IOP is warranted.The prostaglandin analogues such as latanoprost are a highly effective and safe mode of first-line monotherapy as well as adjunctive therapy in patients who fail to achieve optimal IOP control with other classes of glaucoma agents.This offers clinicians the opportunity to tailor treatment strategies that optimize IOP lowering. Studies confirm that once-daily topical instillation of latanoprost 0.005% solution produces a robust and sustained IOP reduction of between 20% and 40% in adults with open-angle glaucoma or ocular hypertension. Latanoprost is well tolerated with minimal to no adverse ocular or systemic effects.
